WO1996023889A1 - Rekombinanter rna-virus-vektor und verfahren zur herstellung desselben - Google Patents
Rekombinanter rna-virus-vektor und verfahren zur herstellung desselben Download PDFInfo
- Publication number
- WO1996023889A1 WO1996023889A1 PCT/EP1996/000334 EP9600334W WO9623889A1 WO 1996023889 A1 WO1996023889 A1 WO 1996023889A1 EP 9600334 W EP9600334 W EP 9600334W WO 9623889 A1 WO9623889 A1 WO 9623889A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- sequence
- recombinant rna
- rna virus
- vector according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5425—IL-9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to a recombinant RNA virus vector, a method for producing the recombinant RNA virus vector and the use thereof for producing a medicament.
- eukaryotic systems such as the Se liki Forest virus system (Liljeström P., Garoff H. 1991, Bio / Technology 9, 1356-1361) are based on an RNA-dependent principle; due to their pathogenic potential, they cannot be used in vivo.
- RNA-coded viruses the so-called retro viruses.
- the expression of foreign genes in such vector systems is not solely dependent on translation, but only takes place after integration into the genomic DNA of the target cell.
- Retroviral vector systems interact as cDNA in the genome of the target cell. All constructs suitable for transcription must have regulatory and processing sequences.
- the object of the present invention is to eliminate the disadvantages of the prior art by means of a new vector system and to provide a method for producing the vector system. stems as well as compilations and possible uses.
- RNA virus vector for influencing cells in particular for gene therapy, is provided, the sequence of which is changed by removing at least one sequence section necessary for replication competence and by inserting at least one foreign sequence section such that expression of a Virus different sequence can be reached, mediated or disabled.
- the advantage of this system is, in particular, that no transcription-regulating sequences are required.
- the vector system according to the invention does not necessarily lead to lethal damage to the infected cells and, because of its primarily transient expression property, is suitable for in vivo or ex vivo application to the patient.
- At least one helper cell, helper cell line or a helper virus is suitably provided.
- the sequence other than the wild-type virus can be an antisense or ribozyme sequence for blocking or destroying a viral RNA or DNA molecule.
- the sequence is derived from a positive-strand RNA virus, preferably a Picorna virus, and as a Picorna virus a polio virus. preferably use an attenuated polio virus. This ensures the expression of specific RNA sequences in the cytoplasmic region with high transfection efficiency.
- a part of the coding vector sequence preferably the structure protein coding sequence, can be removed and the foreign sequence can be a protein coding, in particular a cDNA sequence. It is advantageous if the recombinant RNA virus vector has a plurality of internal ribosomal binding sites, preferably that of encephalomyocarditis, polio, foot-and-mouth disease or hepatitis A virus.
- the helper virus can be expressed transiently or permanently in eukaryotic cells. It is useful to derive the helper virus from the polio virus.
- a "suicide gene” can be produced contrary to the reading direction of the same RNA virus vector and a combination with such sequence elements is provided which, when a reverse transcriptase and in particular a “primer” are present binding site "which enables treatment of retroviral cells such as cells containing HIV provirus.
- a method for producing a recombinant RNA virus vector according to the invention in which at least one sequence section necessary for replication competence is removed from the sequence of a preferably double-stranded copy of a wild-type virus, at least one foreign sequence section is inserted and the recombinant RNA virus vector is introduced into a production cell for supplementation.
- the production cell is advantageously a helper cell or a helper cell line. It can in the «A helper virus is introduced for the production cell. It is advantageous if the recombinant RNA virus vector is cloned behind a transcription site of a eukaryotic expression vector or a prokaryotic promoter.
- the recombinant RNA virus is provided with an infectious envelope by the helper cell line or an infectious envelope is provided by the helper virus in the production cell.
- the recombinant RNA virus vector according to the invention can be used for the production of a medicament for transient gene therapy as well as for the treatment of tumor or autoimmune diseases and for wound treatment.
- the treatment of retrovirally infected cells, in particular HIV-provirus-containing cells, is also possible.
- the use of the recombinant RNA virus vector according to the invention for the production of a medicament for the oral administration of proteins and / or nucleic acids is important.
- a preferred use of the invention is the production of clones which code for a gene which activates the immune system and which are suitable for use as a medicament for the genetic therapy of tumor patients.
- Interleukins such as are here as immunomodulatory substances
- IL-2, IL-10, GMCSF, GCSF and immunologically relevant adhesion molecules such as CD2, CD4, CD8, LFA-1, 4F2, CD40 and CD28 and their ligands LFA-3, ICAM-1, B7 or CD45.
- These genes are preferably expressed in recombinant polio viruses instead of the viruseigenic structural proteins.
- the virus proteins necessary in ice remain expressed by the use of a signal which allows a polycistronic sequence of genes and their expression, an internal ribosomal entry site (IRES).
- a method for transient gene therapy uses a recombinant RNA virus vector according to the invention to influence a host cell, the expression of a sequence different from the wild-type virus being achieved, mediated or hindered.
- a further solution to the above object is achieved by the provision of a kit or a combination of means for carrying out the method.
- immunostimulating substances makes cancer therapy feasible ex vivo and in vivo; the cloning of suicide genes makes ablation of certain cell types, e.g. virus-infected cells possible with HIV infection.
- An application of the invention for the treatment of autoimmune diseases is the production of clones which are suitable for an apoptosis-inducing gene, e.g. the receptor fas, the tumor suppressor gene p53 or the early adenovirus gene EIA, code or for a so-called suicide gene and its surface properties are preferably changed so that they bind specifically to cells of the immune system that recognize a certain autoantigen or its epitope and infect these cells.
- an apoptosis-inducing gene e.g. the receptor fas, the tumor suppressor gene p53 or the early adenovirus gene EIA, code or for a so-called suicide gene and its surface properties are preferably changed so that they bind specifically to cells of the immune system that recognize a certain autoantigen or its epitope and infect these cells.
- TNF ⁇ which also causes apoptotic and necrotic cell death, also aims in this direction. calls, as well as the genes known as suicide genes TK and CDD.
- Certain immunologically relevant cells can also be switched off by induction of energy by means of the depletion of primary receptor molecules (for example by means of antisense constructs) or the receptor-associated motifs (Reth motifs). Specificity for target cells of this type can be achieved by replacing the main antigen of VP1 with the reaction-triggering antigen or by targeted receptor recognition. In the case of target cells carrying CD4, for example, the corresponding epitope of the HI virus (gpl20-V3) is appropriate.
- Such clones can be administered to autoimmune-reactive patients, preferably systemically, and affect the autoimmune-reactive cells.
- a suicide gene or an apoptosis-inducing gene is expressed there. This leads to a higher specificity with regard to the target cells.
- Another preferred application of the invention uses genes which lead to the death of the target cells. These still contain a specified specificity for a target cell group, e.g. Cd-4 or Cd-26-bearing cells, as a therapeutic against an existing HIV infection.
- a target cell group e.g. Cd-4 or Cd-26-bearing cells
- the killing of potential target cells of the HIV virus and of cells in which the HIV virus is integrated leads to a remission of the infection, particularly in the phase of low viral load.
- Another preferred application is the expression of anti-inflammatory molecules in the therapy of partially. tissue-destructive autoimmunopathies.
- the method for producing the recombinant RNA virus vector according to the invention can in particular have the following steps: In a first step, a double-stranded cDNA copy of an RNA virus, preferably an attenuated polio virus, is made available, produced, obtained or otherwise acquired (vector DNA). This cDNA copy is preferably in a prokaryotic replication system.
- areas are cut out of the cDNA construct according to the size of the gene to be cloned. These are primarily sequences whose function can be replaced in trans, preferably encoded envelope proteins, in the case of the polio virus the genes VP4, VP3, VP2 and / or VP1. The sequences necessary for expression in ice, the recognition sites for the proteases necessary for processing, the internal ribosomal binding sites and the polymerases are retained.
- the transsupplementation with the removed genes is ensured by a helper virus or a helper cell line.
- the gene to be newly expressed in the viral genome is preferably named after a suitable internal one
- Ribosomal binding site internal ribosomal entry
- the gene to be cloned preferably ends with a stop codon and has a new IRES and a methionine for a new initiation of translation of the subsequent proteins of the virus
- Sequence usually has approximately the same sequence length as the removed fragment.
- the fragments supplementing in trans are sufficiently provided by a helper virus or, preferably, a helper cell line, the expression of toxic products, e.g. of the complete PI fragment, is usually avoided or restricted.
- the replication-defective recombined polio virus genome is transferred to the production cell and expressed in a eukaryotic expression vector.
- the recombinant polio virus RNA can also be obtained after in vitro transcription and transfection, e.g. Electroporation, in the production cell.
- the recombinant polio virus RNA is packed in the production cell in infectious particles.
- helper virus can also be used, which due to missing genome areas can no longer be packaged into viral particles. Recombination of the helper virus and the recombinant expression virus should preferably be avoided.
- infectious particles which contain the recombinant expression virus are preferably obtained from the supernatant of the cell culture or from the cytoplasm of infected cells.
- infectious particles with recombinant virus genome are used to infect target cells. These can be cells kept in cell culture, clones, ex vivo explants or systemic or tissue-specific applications of whole organisms.
- a fragment of the cDNA of a Sabin 1 poliovirus (vaccine strain) is cloned via its Celli and SnaBI interfaces.
- the cDNA of the human IL-2 gene is inserted into this fragment via adapters and the Muni and Spei interfaces.
- the IL-2 coding region is followed by a second internal ribosomal entry site (IRES, internal ribosome binding site) of the EMC virus.
- IRES internal ribosomal entry site
- stop codons are located in all three reading frames.
- the subgenomic fragment of the poliovirus obtained with the IL-2 gene and the second IRES is now inserted into the original construct. Transcription with T7 RNA polymerase provides the recombinant full-length RNA.
- the sequences between the first (item 3913) and the last (item 6770) HincII site are removed from the starting vector which can be transcribed with T7 RNA polymerase.
- the RNA transcript of this construct provides the structural proteins required for packaging when co-infected. Cotransfection of both recombinant RNAs leads to the packaging of the recombinant full-length encoding IL-2 RNA in virus envelopes and thus to recombinant polio-viruses, which are used to infect tumor cells.
- Tumor cells and fibroblasts are obtained by biopsy, cultivated in vitro and lethally irradiated and separated. The tumor cells are frozen in aliquots of 107 cells at -180O c. The fibroblasts are transfected by coincubation with a recombinant poliovirus. The vaccination is carried out after lethal irradiation of the fibroblasts and autologous tumor cells with 10,000 rad. Subcutaneous administration is carried out immediately afterwards.
- Tumor therapy can alternatively be achieved by in vivo application of the attenuator t ized recombinant poliovirus for direct infection, eg solid tumors.
- Example 2 Analogously to Example 1, the cDNA of the human fas receptor gene is used and the corresponding recombinant full-length RNA from the polio virus and the helper construct are obtained. Co-transfection of both recombinant RNAs leads to fas encoding recombinant polioviruses, which are used to infect cells to be ablated. Epitopes of an endogenous antigen, such as that of the acetylcholine receptor in patients with myasthenia gravis, are inserted into the main antigen site of the poliovirus instead of the sequence NSAST-KNKDK in the helper construct and lead to preferential uptake of the poliovirus into these autoreactive lymphocytes.
- an endogenous antigen such as that of the acetylcholine receptor in patients with myasthenia gravis
- recombinant polio viruses coding for the human p53 tumor suppressor gene are obtained.
- region V3 of the HIV glycoprotein gpl20 the recombinant polio virus can be delivered to the same target cells as the HIV.
- Expression of the p53 gene now induces cell death in all cells expressing CD4 and thus in all cells that contain HIV provirus.
- the epitope of the protein region gpl20-V3 is inserted into the main antigen site of the poliovirus instead of the sequence NSAST-KNKDK analogously to Example 2.
- the production and application of recombinant viruses is carried out analogously to Example 2.
- recombinant polio viruses which are used for anti-inflammatory genes, e.g.
- the genes which code for IL-10, IL13, IL-4, TGFß or the TNF ⁇ -T55 receptor are carried out analogously to Examples 1 and 2 in Hep-2 cells.
- the recombinant viruses obtained are used to infect isolated body cells.
- IRES in front of the polyprotein, which is broken down into various end products by processing by various proteases, including the virus-specific P2A and P3D.
- the resulting proteins can be seen in the drawing. They can be divided into structural proteins (VP1 to VP4) and nutritional proteins.
- the former form the envelope of the virus, the latter perform different functions in the life cycle of the virus.
- the helper construct shown in FIG. 3 provides the structural proteins missing from the vector shown in FIG. 2. However, it is not packed itself.
- the polyprotein of the starting vector is processed by various proteases, including the viral P2A and P3D, broken down into various end products.
- Part of the virus genome (from VP4 to VP2, VP3 to VP1) is replaced by the human GMCSF gene and the subsequent virus proteins are controlled by an additional IRES.
- the antigenic epitopes of the virus envelopes e.g. the main epitope in VP1, be changed.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU52598/96A AU5259896A (en) | 1995-02-01 | 1996-01-29 | Recombinant rna viral vector and method of preparing the same |
US08/894,170 US6255104B1 (en) | 1995-02-01 | 1996-01-29 | Recombinant poliovirus vector and method of preparing the same |
EP96900980A EP0804598A1 (de) | 1995-02-01 | 1996-01-29 | Rekombinanter rna-virus-vektor und verfahren zur herstellung desselben |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19503082A DE19503082A1 (de) | 1995-02-01 | 1995-02-01 | Gegenstand und Verfahren zur bevorzugt transienten Expression und möglichen Translation spezifischer RNA im cytoplasmatischen Bereich höherer eukaryontischer Zellen |
DE19503082.6 | 1995-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996023889A1 true WO1996023889A1 (de) | 1996-08-08 |
Family
ID=7752794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1996/000334 WO1996023889A1 (de) | 1995-02-01 | 1996-01-29 | Rekombinanter rna-virus-vektor und verfahren zur herstellung desselben |
Country Status (5)
Country | Link |
---|---|
US (1) | US6255104B1 (de) |
EP (1) | EP0804598A1 (de) |
AU (1) | AU5259896A (de) |
DE (1) | DE19503082A1 (de) |
WO (1) | WO1996023889A1 (de) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004319A1 (en) * | 1989-09-25 | 1991-04-04 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
EP0632129A1 (de) * | 1993-06-03 | 1995-01-04 | Bayer Ag | Rekombinante Foamy-Virus-Vektoren zur medizinischen und diagnostischen Verwendung und Verfahren zur Herstellung rekombinanter Foamy-Virus-Vektoren |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4650764A (en) * | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
US5166057A (en) * | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
AU4259193A (en) * | 1992-04-28 | 1993-11-29 | Frank Andreas Harald Meyer | Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament |
DE4225094A1 (de) * | 1992-04-28 | 1993-11-04 | Frank Andreas Harald Meyer | Medikament zur gentherapeutischen behandlung von menschen, tieren und pflanzen, insbesondere zur blockierung der virenvermehrung und der tumorgene sowie verfahren zur herstellung des medikaments |
IL102404A0 (en) * | 1992-07-03 | 1993-01-14 | Daniel Zurr | Method and means for the production of gene products |
ZA937164B (en) * | 1992-09-28 | 1994-05-23 | Commw Scient Ind Res Org | Delivery system |
US5614413A (en) * | 1993-07-01 | 1997-03-25 | The Uab Research Foundation | Encapsidated recombinant poliovirus nucleic acid and methods of making and using same |
US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
-
1995
- 1995-02-01 DE DE19503082A patent/DE19503082A1/de not_active Withdrawn
-
1996
- 1996-01-29 AU AU52598/96A patent/AU5259896A/en not_active Abandoned
- 1996-01-29 US US08/894,170 patent/US6255104B1/en not_active Expired - Fee Related
- 1996-01-29 WO PCT/EP1996/000334 patent/WO1996023889A1/de not_active Application Discontinuation
- 1996-01-29 EP EP96900980A patent/EP0804598A1/de not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004319A1 (en) * | 1989-09-25 | 1991-04-04 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
EP0632129A1 (de) * | 1993-06-03 | 1995-01-04 | Bayer Ag | Rekombinante Foamy-Virus-Vektoren zur medizinischen und diagnostischen Verwendung und Verfahren zur Herstellung rekombinanter Foamy-Virus-Vektoren |
Non-Patent Citations (6)
Title |
---|
D.C. PORTER ET AL.: "Encapsidation of genetically engineered poliovirus minireplicons which express HIV-1 gag and pol proteins upon infection", JOURNAL OF VIROLOGY, vol. 67, no. 7, 1993, pages 3712 - 3719, XP002005021 * |
M. GIRARD ET AL.: "Potential use of poliovirus as a vector", BIOLOGICALS, vol. 21, 1993, pages 371 - 377, XP002005023 * |
P.J. BRENDENBEEK ET AL.: "Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs", JOURNAL OF VIROLOGY, vol. 67, no. 11, 1993, pages 6439 - 6446, XP002005025 * |
R. LEVIS ET AL.: "Engineered defective interfering RNAs of Sindbis virus express bacterial chloramphenicol acetyltransferase in avian cells", PROCEEDINGS OF NATIONAL ACADEMY OF SCIENCE USA, vol. 84, 1987, pages 4811 - 4815, XP002005024 * |
W.S. CHOI ET AL.: "Expression of HIV-1 gag, pol and env proteins fron chimeric HIV-1 poliovirus minireplicons", JOURNAL OF VIROLOGY, vol. 65, no. 6, 1991, pages 2875 - 2883, XP002005022 * |
Z. MOLDOVEANU ET AL.: "Immune responses induced by administration of encapsidated poliovirus replicons which express HIV-1 gag and envelope proteins", VACCINE, vol. 13, no. 11, 1995, pages 1013 - 1022, XP002005020 * |
Also Published As
Publication number | Publication date |
---|---|
DE19503082A1 (de) | 1996-08-08 |
US6255104B1 (en) | 2001-07-03 |
EP0804598A1 (de) | 1997-11-05 |
AU5259896A (en) | 1996-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69731075T2 (de) | Gemisch aus rekombinanten vaccinia-vektoren als polygeur-impfstoff gegen hiv | |
EP1776460B2 (de) | Verfahren zur modulation der genexpression durch änderung des cpg gehalts | |
DE60023600T2 (de) | Replizierende retrovirale Konstrukte, ihre Herstellung und Verwendungen für den Gentransfer | |
DE69836643T2 (de) | Zusammensetzungen für die zufuhr von genen an antigen-präsentierende zellen der haut | |
DE69936577T2 (de) | Lentivirale Verpackungszellen | |
DE60028066T2 (de) | Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen | |
EP0778349A2 (de) | Genkonstrukt und dessen Verwendung | |
EP3189856B1 (de) | Verfahren zur hemmung des ebola-virus über mirna | |
DE4318387A1 (de) | Rekombinante Foamy Virus Vektoren für medizinische und diagnostische Anwendungen sowie Verfahren zur Herstellung von rekombinanten Foamy Virus Vektoren | |
DE69627644T2 (de) | Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie | |
DE102004037611B4 (de) | Induzierbare Genexpression | |
DE69626681T2 (de) | Konditionell-replizierende virale vektoren und ihre verwendung. | |
EP1504107A1 (de) | Rekombinantes fowlpox-virus | |
EP0804598A1 (de) | Rekombinanter rna-virus-vektor und verfahren zur herstellung desselben | |
DE69835369T2 (de) | Alphavirus-vektoren | |
EP1553977B1 (de) | Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze | |
DE19858441C2 (de) | FV-Vektoren zur Expression von Fremdgenen in Säugern und deren Verwendung | |
EP1428886B1 (de) | Verbesserte retrovirale Vektoren für die Gentherapie | |
DE19608751B4 (de) | Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen | |
DE10055545A1 (de) | Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen | |
DE60104406T2 (de) | Modifizierte nodavirus-rns für die genverabreichung | |
DE60021523T2 (de) | Zusammensetzung und verfahren zur immunisierung gegen ein oder mehrere antigene mittels verschiedener rekombinanter vektoren | |
DE19709512A1 (de) | Verfahren für die Herstellung von attenuierten lebenden, rekombinanten Influenza A-Viren mit inkorporierten fremden Glykoproteinen zur Verwendung als nasal/orale Vakzinen und als genetische Vektorsysteme | |
DE19707273C1 (de) | Expressionsvektor zur dauerhaften Expression einer Fremd-DNA | |
WO2000065075A1 (de) | Verwendung von coxsackieviren zur verbesserung der transfektion von zellen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN JP KR RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996900980 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996900980 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08894170 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996900980 Country of ref document: EP |